Mitchell H. Finer, PhD

Mitchell (Mitch) H. Finer, Ph.D., joined MPM Capital as Managing Director in mid-2015. Since then he has founded Oncorus Inc, focused on the development of Oncolytic herpes viruses for the treatment of GBM and other malignancies, where he serves as CEO and CSO. He is also a founder and the interim CEO of CODA Biotherapeutics, focused on developing a chemogenetic neuromodulation platform for the treatment of severe neurological disorders. Mitch also serves on several MPM portfolio company boards, including Semma, Oncorus, TCR2 and CODA Biotherapeutics.

For three decades, Mitch has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine, working to develop products from conception through phase III clinical programs in the US and Europe. Prior to MPM, Mitch served as CSO of bluebird bio, where he was responsible for the strategic build of bluebird’s gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of BLUE’s CART and genome engineering programs.

Prior to bluebird bio, Mitch has served as CEO of Intracel Corporation and Genteric Inc, and as VP Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and SVP of Development at Novacell (now Viacyte). Mitch also successfully co-founded retinal disease gene therapy company Avalanche Biotechnologies (now Adverum Biotechnologies) where he now serves as a member of the Board of Directors.

Mitch received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a BS in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at MIT.

Return to Leadership